Celgene Corporation (CELG)
(Delayed Data from NSDQ)
$96.88 USD
+1.67 (1.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $96.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.88 USD
+1.67 (1.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $96.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Celgene (CELG) Beats Q2 Earnings & Sales Estimates, Ups View
by Zacks Equity Research
Celgene (CELG) reports better-than-expected results for the second-quarter, on the back of growth in Revlimid sales. The company also raises its annual guidance.
Celgene (CELG) Beats on Q2 Earnings, Ups View
by Ekta Bagri
Celgene Corporation (CELG) topped on both earnings and sales in the second quarter driven by Revlimid growth. The company also upped its guidance.
Drug Stocks to Report Earnings on Jul 26: AMGN, ALXN & More
by Zacks Equity Research
Let's see how these five pharma/biotech stocks are poised ahead of their scheduled results on Jul 26.
Celgene (CELG) Q2 Earnings: Disappointment in Store?
by Zacks Equity Research
Celgene Corporation (CELG) has been sailing in troubled waters, of late, and the recent pipeline setbacks might weigh on its performance in its second-quarter results.
Agios (AGIO) Secures FDA Approval for Leukemia Drug Tibsovo
by Zacks Equity Research
Agios (AGIO) gains an FDA approval for its lead pipeline candidate, Tibsovo, for the treatment of relapsed/refractory acute myeloid leukemia (AML) in patients with an IDH1 mutation.
4 Biotech Bets to Watch as Industry Rebounds in a Month
by Madhu Goel
The biotech sector makes a sharp rise in 30 days post the positive data read out from Biogen's mid-stage Alzheimer's trial on BAN2401. We recommend a few industry players for investors' portfolio boost.
Celgene Reports Positive Data on Tecentriq, Abraxane Study
by Zacks Equity Research
Celgene (CELG) reports positive results from a late-stage study on the combination of oncology drug, Abraxane, with immuno-oncology drug, Tecentriq, in advanced breast cancer patients.
Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More
by Zacks Equity Research
Biogen's results from a phase II study in the much-pursued Alzheimer's disease was all over the biotech sector last week.
Celgene, Acceleron Report Positive Data on Thalassemia Drug
by Zacks Equity Research
Celgene (CELG) and partner Acceleron Pharma report positive results on luspatercept from a late-stage study. This is the second positive phase III study for the candidate.
CTI BioPharma Falls After Failure of Pivotal Lymphoma Study
by Zacks Equity Research
CTI BioPharma (CTIC) and partner Servier announce that a pivotal study evaluating a Pixuvri combination regimen in non-Hodgkin lymphoma fails to improve progression free survival.
Biotech ETFs Surge on Biogen's Positive Drug Trial Result
by Sweta Killa
Biotech ETFs surge on Biogen's encouraging Phase 2 clinical study data for Alzheimer???s treatment.
Celgene (CELG) Down 21% So Far in 2018: What Lies Ahead?
by Zacks Equity Research
Celgene's (CELG) shares decline 21%, in the year-to-date period, on pipeline setbacks. However, we expect a better performance in the second half.
Why Biotech Stocks Rallied on Biogen's Alzheimer's Test
by Ryan McQueeney
Several major biotech stocks rallied on Friday after Biogen (BIIB) reported positive results from a Phase 2 study of its Ban2401 therapy, which seeks to reduce toxic amyloid proteins associated with cognitive decline and Alzheimer's disease.
Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More
by Zacks Equity Research
Key headlines in the biotech sector last week include Gilead getting positive CHMP opinion, Keryx plunging on merger news while Celgene and Amgen came out with pipeline updates.
Celgene's Luspatercept Meets Primary Endpoint in the Study
by Zacks Equity Research
Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) announces top-line results from a phase III, multi-center study (MEDALIST), where its pipeline candidate luspatercept met both the primary and secondary endpoints.
Sanofi (SNY) Finalizes Deal for European Generic Unit Sale
by Zacks Equity Research
Sanofi (SNY) finalizes sale of its European generic unit, Zentiva, for $2.2 billion.
4 Biotech Stocks to Bet on in the Second Half of 2018
by Ekta Bagri
While the first half did not turn out to be great for the biotech sector, the second half is expected to be much better. Here, we list four biotechs poised for a good run.
Agios Out-Licenses China Rights to Leukemia Drug Tibsovo
by Zacks Equity Research
Agios (AGIO) and CStone Pharmaceticals sign an exclusive collaboration and license agreement for the development and commercialization of its lead pipeline candidate Tibsovo.
Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant
by Zacks Equity Research
Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant
Drug Stocks: The Next Hot Industry or Value Traps?
by Tracey Ryniec
These 5 stocks look dirt cheap but is it too good to be true?
Amgen Gets FDA Nod to Add ASPIRE Data on Kyprolis Label
by Zacks Equity Research
Amgen (AMGN) gets FDA approval to add overall survival data from the phase III ASPIRE study on the label of its multiple myeloma drug, Kyprolis.
Alexion-Complement Pharma Tie Up to Treat Neuro Disorders
by Zacks Equity Research
Alexion (ALXN) teams up with Complement Pharma to co-develop its C6 inhibitor, CP010, for neurodegenerative disorders.
Top Research Reports for Disney, Caterpillar & MetLife
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Disney (DIS), Caterpillar (CAT) and MetLife (MET).
Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO
by Zacks Equity Research
The biotech sector was in focus last week due to the ASCO meet at Chicago where biotech bigwigs presented data on their oncology drugs and promising pipeline candidates.
Celgene Presents Data on CAR T Therapy, Revlimid & Pomalyst
by Zacks Equity Research
Biotech major Celgene presents encouraging data on its oncology drugs Revlimid, Pomalyst along with other experimental therapies at the ASCO.